Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Phase II Study of Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Next Previous
X
Search
Trial Profile

A Prospective Phase II Study of Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vindesine (Primary) ; Zanubrutinib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Jun 2023 Results (as of 14th February,2023, n=23) assessing safety and activity of zanubrutinib plus R-CHOP for patients with previously untreated Large B Cell Lymphoma presented at the 28th Congress of the European Haematology Association
    • 14 Dec 2021 Interim results (as of 15th July 2021; n=9) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 27 May 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top